Arbor Biotechnologies
Diverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – for accelerating the discovery of proteins for improving human health and sustainability.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | $73.9m Valuation: $1.1b | Series C | |
| Total Funding | 000k | ||
Related Content
Arbor Biotechnologies is an early-stage life sciences company at the forefront of biodiscovery. Leveraging cutting-edge technologies such as artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor is revolutionizing the discovery of proteins that can significantly improve human health and biotechnologies. The company is dedicated to developing curative genetic medicines for patients with serious genetic diseases by understanding the underlying genetic pathology of these conditions. Arbor's extensive toolbox of CRISPR-based genomic editors allows for tailored therapeutic approaches, unlocking advancements that have the potential to transform patient outcomes.
Arbor primarily serves the healthcare sector, focusing on patients with genetic disorders. The company operates within the biotechnology market, utilizing a business model that centers on research and development partnerships, such as its collaboration with Vertex Pharmaceuticals to develop ex vivo engineered cell therapies. Arbor generates revenue through these strategic partnerships and the commercialization of its proprietary CRISPR technology.
Keywords: CRISPR, genomic editors, genetic diseases, artificial intelligence, genome sequencing, gene synthesis, high-throughput screening, therapeutic advancements, biotechnology, healthcare.